Other
Anticoagulant
0
Pipeline Programs↗
10
Active Trials↗
10
Companies Involved↗
Anticoagulant is an early-stage landscape with 0 programs across 10 companies. The most active players are Boehringer Ingelheim, AstraZeneca, Johnson & Johnson.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
60
clinical trials
Completed39 · 65%
Unknown status7 · 12%
Recruiting5 · 8%
Terminated4 · 7%
Active, not recruiting4 · 7%
Not yet recruiting1 · 2%
Clinical Trials
Trial Activity
60 trials
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
Recruiting·—·N/A·NCT04262492·500 enrolled
Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis
Recruiting·—·N/A·NCT06386107·212 enrolled
Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)
Recruiting·—·Phase 1·NCT06204237·10 enrolled
Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant
Active, not recruiting·—·Phase 1·NCT06372483·40 enrolled
DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers
Active, not recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT05750680·23 enrolled
Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin
Active, not recruiting·—·Phase 1·NCT06517563·16 enrolled
Prospective Study: TXA, Anticoagulant, Orthopaedic Trauma
Not yet recruiting·—·Phase 4·NCT07116395·200 enrolled
Periprocedural Direct Oral Anticoagulant Management
Completed·FFundación para la Investigación del Hospital Clínico de Valencia·N/A·NCT03182218·1,100 enrolled
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
Completed·—·Phase 1·NCT05152420·105 enrolled
Replication of the ROCKET-AF Anticoagulant Trial in Healthcare Claims Data
Completed·—·N/A·NCT04593056·102,636 enrolled
Replication of the RELY Anticoagulant Trial in Healthcare Claims Data
Completed·—·N/A·NCT04593043·78,140 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)